Sera Prognostics (NASDAQ:SERA) Stock Price Down 2.3% – Here’s Why

Sera Prognostics, Inc. (NASDAQ:SERA) shares dropped 2.3% during mid-day trading on Friday . The company traded as low as $2.40 and last traded at $2.51. Approximately 26,637 shares traded hands during mid-day trading, an increase of 8% from the average daily volume of 24,570 shares. The stock had previously closed at $2.57.

Analyst Ratings Changes

Several brokerages have recently issued reports on SERA. Weiss Ratings restated a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday, December 29th. Jefferies Financial Group raised shares of Sera Prognostics to a “strong-buy” rating in a report on Monday, December 15th. Finally, Wall Street Zen upgraded shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Sera Prognostics Stock Down 2.3%

The business has a 50-day moving average price of $3.12 and a 200-day moving average price of $3.07. The firm has a market capitalization of $96.89 million, a P/E ratio of -3.26 and a beta of 0.98.

Insider Activity

In other news, CEO Zhenya Lindgardt sold 28,215 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $3.04, for a total transaction of $85,773.60. Following the completion of the transaction, the chief executive officer directly owned 768,081 shares of the company’s stock, valued at approximately $2,334,966.24. This trade represents a 3.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 50,366 shares of company stock valued at $156,296. Corporate insiders own 13.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Aberdeen Group plc boosted its holdings in Sera Prognostics by 2.3% during the third quarter. Aberdeen Group plc now owns 2,279,699 shares of the company’s stock valued at $6,976,000 after purchasing an additional 52,332 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Sera Prognostics by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock worth $3,725,000 after buying an additional 54,008 shares during the period. Citadel Advisors LLC boosted its stake in Sera Prognostics by 1.9% in the 3rd quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock valued at $2,000,000 after buying an additional 12,439 shares in the last quarter. Captrust Financial Advisors boosted its stake in Sera Prognostics by 20.0% in the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after buying an additional 100,366 shares in the last quarter. Finally, Corient Private Wealth LLC grew its position in Sera Prognostics by 73.9% in the second quarter. Corient Private Wealth LLC now owns 100,000 shares of the company’s stock valued at $277,000 after acquiring an additional 42,500 shares during the period. Institutional investors and hedge funds own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.